BridgeBio Pharma (BBIO) Capital Expenditures (2018 - 2026)
BridgeBio Pharma recorded quarterly Capital Expenditures of $69000.0 in Q1 2026, down 93.64% quarter-over-quarter from $1.1 million in Q4 2025, and down 79.53% year-over-year from $337000.0 in Q1 2025.
BridgeBio Pharma's Capital Expenditures history runs 9 years deep, the most recent figure standing at $69000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 79.53% year-over-year to $69000.0; the TTM figure through Mar 2026 stood at $829000.0 (down 30.92% YoY), while the FY2025 annual figure was $1.1 million, up 17.58% from the prior year.
- Capital Expenditures came in at $69000.0 for Q1 2026 at BridgeBio Pharma, down from $1.1 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.1 million in Q4 2025 to a low of -$786000.0 in Q2 2022.
- A 5-year average of $215750.0 and a median of $94500.0 in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures jumped 5792.31% in 2023 and sank 171.32% in 2025, its largest moves.
- BridgeBio Pharma's Capital Expenditures stood at -$13000.0 in 2022, then jumped by 3446.15% to $435000.0 in 2023, then slumped by 89.2% to $47000.0 in 2024, then jumped by 2208.51% to $1.1 million in 2025, then slumped by 93.64% to $69000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $69000.0, $1.1 million, and -$582000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 21.83 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | 69,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69,000.00 |
| Mar 31, 2026 | 69,000.00 |
| Dec 31, 2025 | 1.09 Mn |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | -582,000.00 |
| Sep 30, 2025 | -582,000.00 |
| Jun 30, 2025 | 257,000.00 |
| Jun 30, 2025 | 257,000.00 |
| Mar 31, 2025 | 337,000.00 |
| Mar 31, 2025 | 337,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Sep 30, 2024 | 816,000.00 |
| Sep 30, 2024 | 816,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Dec 31, 2023 | 435,000.00 |
| Dec 31, 2023 | 435,000.00 |
| Sep 30, 2023 | 740,000.00 |
| Sep 30, 2023 | 740,000.00 |
| Jun 30, 2023 | 119,000.00 |
| Jun 30, 2023 | 119,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Dec 31, 2022 | -13,000.00 |
| Dec 31, 2022 | -13,000.00 |
| Sep 30, 2022 | -13,000.00 |
| Sep 30, 2022 | -13,000.00 |
| Jun 30, 2022 | -786,000.00 |
| Jun 30, 2022 | -786,000.00 |
| Mar 31, 2022 | 859,000.00 |
| Mar 31, 2022 | 859,000.00 |
| Dec 31, 2021 | 2.54 Mn |
| Dec 31, 2021 | 2.54 Mn |
| Sep 30, 2021 | 6.46 Mn |
| Sep 30, 2021 | 6.46 Mn |
| Jun 30, 2021 | 2.29 Mn |
| Jun 30, 2021 | 2.29 Mn |
| Mar 31, 2021 | 1.96 Mn |
| Mar 31, 2021 | 1.96 Mn |
| Dec 31, 2020 | -4.27 Mn |
| Dec 31, 2020 | -4.27 Mn |
| Sep 30, 2020 | 549,000.00 |
| Sep 30, 2020 | 549,000.00 |
| Jun 30, 2020 | 346,000.00 |
| Jun 30, 2020 | 346,000.00 |
| Mar 31, 2020 | 4.48 Mn |
| Mar 31, 2020 | 4.48 Mn |
| Dec 31, 2019 | 1.75 Mn |
| Dec 31, 2019 | 1.75 Mn |
| Sep 30, 2019 | 381,000.00 |
| Sep 30, 2019 | 381,000.00 |
| Jun 30, 2019 | 83,000.00 |
| Jun 30, 2019 | 83,000.00 |
| Mar 31, 2019 | 427,000.00 |
| Mar 31, 2019 | 427,000.00 |
| Dec 31, 2018 | 741,000.00 |
| Dec 31, 2018 | 741,000.00 |
| Sep 30, 2018 | 605,000.00 |
| Sep 30, 2018 | 605,000.00 |